Dynamics of competing SARS-CoV-2 variants during the Omicron epidemic in England영국의 오미크론 전염병 동안 경쟁하는 SARS-CoV-2 변이체의 역학Article Published on 2022-07-282022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] assessment competing cross-sectional survey Cross-sectional surveys Dynamics England Epidemic Epidemics estimate evade exhibited followed by genomic variants immune evasion infection rate initial Lineage magnitude National Neutralising Antibodies omicron Omicron variant population immunity Prevalence replaced resurgence SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 neutralising antibodies SARS-CoV-2 pandemic SARS-CoV-2 variant variant variants [DOI] 10.1038/s41467-022-32096-4 PMC 바로가기 [Article Type] Article
Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan항-SARS-CoV-2 항체의 혈청유병률 및 역학: 우한의 기저 질환 환자를 기반으로 한 종단 연구Article Published on 2022-07-152022-09-11 Journal: Respiratory Research [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] 95% CI All participant All participants anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody Antibody titer Assessing asymptomatic patient asymptomatic patients baseline Blood blood sample Blood samples change Community COVID-19 Diseases door effective family members feature Follow-up Government healthcare Households Humoral immunity IgA IgG IgG antibodies IgG antibody IgG titer IgG titers IgM immunoglobulins individual infected with SARS-CoV-2 list Local local government natural infection Neutralising Antibodies neutralising antibody Neutralizing antibody titer no significant difference nucleocapsid protein participant Participants Patient positive Prevention and control Protein provided questionnaire Randomly remained Research SARS-CoV-2 SARS-CoV-2 nucleocapsid selected serological Seroprevalence serum sample serum samples significantly Single natural infection symptomatic patient Symptomatic patients telephone tested titer total antibodies total antibody underlying disease underlying diseases Underlying diseases. venous venous blood was collected were assessed Wuhan [DOI] 10.1186/s12931-022-02096-5 PMC 바로가기 [Article Type] Article
Covid-19 vaccines and variants of concern: A reviewCovid-19 백신 및 우려 변종: 검토Review Published on 2022-07-012022-09-11 Journal: Reviews in Medical Virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad5-nCoV administration adverse event AZD1222 BBIBP-CorV BNT162b2 caused Cell-mediated immunity Clinical studies CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 disease COVID-19 vaccination COVID-19 vaccines CVnCoV deaths effective vaccine Efficacy Infection mRNA mRNA vaccines mRNA-1273 Mutation nCoV Neutralising Antibodies neutralising antibody nine NVX-CoV2373 outbreak rare adverse events reported Research respiratory SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus Spike protein Spread symptomatic COVID-19 symptomatic COVID-19 disease the SARS-CoV-2 vaccination Vaccine vaccine candidate vaccine candidates vaccine efficacy variant variants variants of concern variants of concern. Viral Viral vector viral vector and mRNA vaccines VOCs Wuhan-Hu-1 ZF2001 [DOI] 10.1002/rmv.2313 PMC 바로가기 [Article Type] Review
COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022COVID-19 백신 접종 및 BA.1 돌발 감염은 BA.4 및 BA.5 오미크론 변이체에 대해 덜 효율적인 중화 항체를 유도, 이스라엘, 2022년 3월~6월Article Published on 2022-07-012022-09-11 Journal: Eurosurveillance [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] BA.4/5 BNT162b2 BNT162b2 vaccination Breakthrough infection COVID-19 COVID-19 vaccination dose Efficiency evaluated healthcare worker Healthcare workers IMPROVE indicated individual induce Infection less neutralising Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres Neutralizing omicron Omicron. SARS-CoV-2 Vaccine vaccine dose variant variants wild type WT virus [DOI] 10.2807/1560-7917.ES.2022.27.30.2200559 PMC 바로가기 [Article Type] Article
Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history백신 접종 및 감염 이력에 의한 SARS-CoV-2 Delta 및 Omicron 변이체에 대한 반응성 중화Article Published on 2022-06-102022-09-11 Journal: Genome Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] Abbott anti-S antibody antibody antibody persistence Antibody Response Antibody titre antibody titres Antigen B.1 B.1.1.529 B.1.617.2 blood sample Blood samples Cohort collected control group control groups controls COVID-19 cross-protective Delta delta variant DiaSorin dose elicited followed by generate group healthcare healthcare worker Immune escape Immunity immunoassays increasingly individuals induce Infection investigated N antigen naïve naïve subject naïve subjects natural infection neutralisation neutralising Neutralising Antibodies nucleocapsid omicron Omicron variant performed persistence Post-infection presence of antibody question reactivity required Roche S antigen SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants sera Serosurvey serum significantly subject subjects tested the SARS-CoV-2 timepoints two groups vaccinated individuals vaccination vaccination. Vaccine Vaccine development variant virus VoC VOCs weakened were used while [DOI] 10.1186/s13073-022-01066-2 PMC 바로가기 [Article Type] Article
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study브라질에서 2회 용량 1차 프로토콜 및 BNT162b2 이종 부스터(Immunita-001)에서 비활성화된 바이러스(CoronaVac) 백신의 면역원성, 효과 및 안전성: 1년 기간의 후속 조치 4상 연구Clinical Trial Published on 2022-06-092022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody antibody antibody levels Antibody titer Antibody titers approach association BNT162b2 booster booster dose Brazil Cellular immune response chemokines CoronaVac coronavirus COVID-19 COVID-19 pandemic Critical Cytokines Delta delta variant dose Effectiveness exposure to followed by growth factor Growth factors Heterologous heterologous booster highest IgG immune Immune profile immune response immunogenicity implication individual individuals Interaction maintenance male median mediators Neutralising Antibodies neutralising antibody no increase omicron Omicron variant pandemic Period phase 4 presenting protocol reduction remained respiratory restored robust Safe Safety SARS-CoV-2 Seropositivity severe acute respiratory syndrome Coronavirus significantly Spread timepoint titer titers vaccination Vaccine vaccine. variant virus Year [DOI] 10.3389/fimmu.2022.918896 PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2 IgG Amongst Dental Workers During the COVID-19 PandemicCOVID-19 전염병 동안 치과 종사자들 사이에서 SARS-CoV-2 IgGArticle Published on 2022-06-012022-09-11 Journal: International dental journal [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] aerosol aerosol-generating procedure aerosol-generating procedures Analysis Asymptomatic contracting the virus COVID-19 COVID-19 transmission cycle dental dental clinic dental hygienists dentist dentistry dentists determine diagnostic Efficacy ELISA enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluate Health IgG IgG levels Immunoglobulin Immunoglobulin G in vitro introduced Laboratory Laboratory test Laboratory tests Neutralising Antibodies neutralising antibody Nurses outbreak pandemic participant Pearson Prevalence professional protocol provided Quantitative questionnaire Questionnaires Research risk risk of COVID-19 SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2. semi-quantitative Seropositivity serum serum IgG study group Study protocol SUB1 the SARS-CoV-2 Transmission were measured worker [DOI] 10.1016/j.identj.2022.02.003 PMC 바로가기 [Article Type] Article
SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s PopulationSM-COLSARSPROT: 전 세계 인구를 대상으로 하는 고 면역원성 초돌연변이 합성 펩타이드Article Published on 2022-05-252022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] Amino acid Antibody titre Antigen presentation approach backbone complementary concerning Coverage Covering disrupting DNA E protein genetic variability Genetic variant genotyped histocompatibility complex human leukocyte antigen immune response induce Interaction leukocyte major histocompatibility complex methodology MHCII modified synthetic peptides molecular multiepitope mutant mutational variants Neutralising Antibodies neutralising antibody pandemic parental peptide peptides physicochemical polymorphism Population predicted replacing residues SARS-CoV-2 SARS-CoV-2 S selected Specific Structure supramutational synthesised synthetic synthetic peptides Trial Vaccine development vaccine for COVID-19 virus worldwide coverage. π-π interaction [DOI] 10.3389/fimmu.2022.859905 PMC 바로가기 [Article Type] Article
SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol심혈관 위험 인자가 있는 환자의 SARS-CoV-2 체액성 면역 반응: 커뮤니티 코호트 연구 프로토콜Article Published on 2022-05-192022-09-11 Journal: BMJ Open [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Adult patients anti-SARS-CoV-2 vaccine anti-SARS-CoV-2 vaccines antibody approved baseline blood sample cardiovascular cardiovascular risk cardiovascular risk factors clinics Cohort collected Community conducted Contact contact with COVID-19 death defined detectable determine disseminate eligible Epidemiology Ethics ethics committee exposure exposure to face-to-face contact follow-up time Health care humoral immune response IgG antibody immunology immunology. Inclusion International Local Memorandum mixed-effects model morbidity National neutralising Neutralising Antibodies neutralising antibody outcome pandemic participant Patient peer-reviewed Prevent primary care Primary outcome Primary outcomes prospective cohort study protocol questionnaire recruitment Registered Research Sample size SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens secondary Secondary outcomes Seroconversion service South strength Study protocol vaccination website [DOI] 10.1136/bmjopen-2022-061345 PMC 바로가기 [Article Type] Article
At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron VariantSARS-CoV-2 오미크론 변이체 중화에 필수적인 주요 백신 최소 3회 투여Article Published on 2022-05-172022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] AlphaFold AstraZeneca biomolecular modelling coronavirus disease Coronavirus disease-19 COVID-19 Delta different time point different time points Donor donors dose equity Essential followed by Gender generate leading limit of detection Moderna neutralisation Neutralising Antibodies neutralising antibody neutralising antibody titres neutralizing antibody titre Older omicron Omicron variants Pfizer plasma samples reduction in SARS-CoV-2 second dose significantly Spike protein timepoints titre titres Vaccine Vaccines variants variants of concern variants of concern. virus neutralization assay virus neutralization assays were assessed [DOI] 10.3389/fimmu.2022.883612 PMC 바로가기 [Article Type] Article